The Quantikine® Human IGF-II Immunoassay is a 3.5 hour solid-phase ELISA designed to measure human IGF-II in cell culture supernates, serum, plasma, and urine. It contains E. coli-expressed recombinant human IGF-II and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human IGF-II showed linear curves that were parallel to the standard curves obt...ained using the Quantikine® kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human IGF-II.
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Human IGF-II/IGF2 Quantikine ELISA Kit
chromosome 11 open reading frame 43
insulin-like growth factor 2 (somatomedin A)
insulin-like growth factor II
insulin-like growth factor type 2
Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity.
The IGFL (insulin-like growth factor-like) family includes four small (~11 kDa), probably secreted family members in humans and one in mouse. This family shares A and B chain cysteine motifs with the IGF superfamily, and has an additional cysteine motif within an uncleaved region corresponding to the C peptide of the IGF family.
Be the first to review our Human IGF-II/IGF2 Quantikine ELISA Kit and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.